东亚药业：部分募集资金用途与招股说明书不一致 收到浙江证监局责令改正行政监管措施

Core Points - East Asia Pharmaceutical (605177.SH) received a corrective measure order from the Zhejiang Regulatory Bureau of the China Securities Regulatory Commission due to discrepancies in the use of raised funds compared to the disclosures in the initial public offering prospectus [1] - The Zhejiang Regulatory Bureau found that the company did not timely perform the necessary review procedures and that the information disclosed regarding the storage and actual use of raised funds was inaccurate [1] - As a result, the Zhejiang Regulatory Bureau decided to implement corrective supervisory measures and record this incident in the securities and futures market integrity file [1]